Advances in risk assessment and prophylaxis for central nervous system relapse in diffuse large B-cell lymphoma.

ABSTRACT: Central nervous sytem recurrence of diffuse large B-cell lymphoma is an uncommon but devastating event, making identification of patients at high risk for relapse within the central nervous system essential for clinicians. Modern risk stratification includes both clinical and biological features. A validated clinical risk model employing the five traditional International Prognostic Index risk factors plus renal or adrenal involvement can identify a high-risk patient population with a central nervous system recurrence risk of greater than 10%. Lymphoma involvement of certain discrete extranodal sites such as the testis also confers increased risk, even in stage I disease. Adverse biological risk factors for central nervous system relapse include presence of translocations of MYC, BCL2 and/

SUBMITTER: Qualls D 

PROVIDER: S-EPMC6312016 | biostudies-literature | 2019 Jan

REPOSITORIES: biostudies-literature